[Combined effect of PT-050 (recombinant human TNF) and antitumor drugs on syngeneic murine tumors].
The combined effect of PT-050 (recombinant human TNF) and various antitumor drugs was investigated using murine colon 26 adenocarcinoma, Meth A sarcoma and B16 melanoma transplanted into syngeneic mice. When colon 26- or Meth A- bearing mice were intravenously given PT-050 in combination with mitomycin C (MMC), doxorubicin (DXR), cis-platinum (CDDP), 5-fluorouracil (5-FU) or cyclophosphamide (CPA), a significant synergistic effect was observed, that is, both the inhibition rate of tumor growth and the cured ratio were increased significantly when compared with those given each drug alone. Similarly, an augmentation of the antitumor effect was also observed in B16-bearing mice by a combined treatment with PT-050 and these antitumor drugs. These results suggest that the combination chemotherapy of PT-050 with various antitumor drugs may be useful for cancer therapy.
D000230:Adenocarcinoma / Q000188:drug therapy; D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage; D003110:Colonic Neoplasms / Q000188:drug therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D006023:Glycoproteins / Q000008:administration & dosage*; D008546:Melanoma, Experimental / Q000188:drug therapy; D051379:Mice; D016685:Mitomycin; D008937:Mitomycins / Q000008:administration & dosage; D009374:Neoplasms, Experimental / Q000188:drug therapy* / Q000473:pathology; D014409:Tumor Necrosis Factor-alpha
D000970:Antineoplastic Agents; D006023:Glycoproteins; D008937:Mitomycins; D014409:Tumor Necrosis Factor-alpha; D016685:Mitomycin; D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin